World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
90
Citations
30403
World Ranking
12186
National Ranking
6249

Marc C. Chamberlain publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Marc C. Chamberlain sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 466 publications — 52nd percentile

52% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Marc C. Chamberlain D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Marc C. Chamberlain sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 90 D-Index — 41st percentile

41% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Marc C. Chamberlain is affiliated with the University of Washington in the United States. Their research primarily focuses on the field of Medicine, with significant contributions in related subfields such as Genetics, Immunology, Oncology, Surgery, and Pulmonary and Respiratory Medicine.

The scientist's work encompasses several medically relevant topics, notably in neuro-oncology and cancer immunology. Main topics of their research include:

  • Glioma Diagnosis and Treatment
  • Brain Metastases and Treatment
  • Immune cells in cancer
  • Inflammation biomarkers and pathways
  • Management of metastatic bone disease
  • Inflammatory Biomarkers in Disease Prognosis
  • Meningioma and schwannoma management

Marc C. Chamberlain has published extensively in multiple venues, with a concentration in neuro-oncological journals. Frequent publication venues include:

  • Neuro-Oncology
  • Neuro-Oncology Advances
  • Journal of Clinical Oncology
  • Investigational New Drugs
  • Journal for ImmunoTherapy of Cancer

Recent publications by Chamberlain include the following:

  • "A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma," 2020, Neuro-Oncology
  • "A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma," 2022, Neuro-Oncology Advances
  • "A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma," 2024, Investigational New Drugs
  • "A phase 1a dose-escalation study of PY314, a TREM2 (Triggering Receptor Expressed on Macrophages 2) targeting monoclonal antibody," 2022, Journal of Clinical Oncology
  • "Phase 1b/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma," 2024, Neuro-Oncology Advances

The scientist frequently collaborates with other researchers. Their most common co-authors include:

  • Amita Patnaik
  • Ira Winer
  • Nadine S. Jahchan
  • Winston Tan
  • Christos E. Kyriakopoulos

Best Publications

  • Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

    Patrick Y. Wen;David R. Macdonald;David A. Reardon;Timothy F. Cloughesy

  • Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors Report of the Quality Standards Subcommittee of the American Academy of Neurology

    M. J. Glantz;B. F. Cole;B. F. Cole;P. A. Forsyth;L. D. Recht;L. D. Recht

  • Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.

    Nathalie L. Albert;Michael Weller;Bogdana Suchorska;Norbert Galldiks

  • A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors.

    Michael J. Glantz;Michael J. Glantz;Kurt A. Jaeckle;Marc C. Chamberlain;Surasak Phuphanich

  • Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas

    M. J. van den Bent;J. S. Wefel;D. Schiff;M. J. B. Taphoorn

  • Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma

    Wolfgang Wick;Vinay K. Puduvalli;Marc C. Chamberlain;Martin J. van den Bent

  • Neoplastic meningitis

    Ana Aparicio;Marc C. Chamberlain

  • Randomized Trial of a Slow-Release Versus a Standard Formulation of Cytarabine for the Intrathecal Treatment of Lymphomatous Meningitis

    Michael J. Glantz;Suzanne LaFollette;Kurt A. Jaeckle;William Shapiro

  • Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma

    Marc C. Chamberlain;Michael J. Glantz;Lisa Chalmers;Alixis Van Horn

  • Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report.

    Sigal Grisariu;Batia Avni;Tracy T. Batchelor;Martin J. van den Bent

  • Adult primary intradural spinal cord tumors: a review.

    Marc C. Chamberlain;Trent L. Tredway

  • Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain.

    Marc C. Chamberlain;Arthur D. Sandy;Gary A. Press

  • Leptomeningeal metastases: a RANO proposal for response criteria.

    Marc Chamberlain;Larry Junck;Dieta Brandsma;Riccardo Soffietti

  • Radiographic patterns of relapse in glioblastoma.

    Marc C. Chamberlain

  • Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review

    Thomas Kaley;Igor Barani;Marc Chamberlain;Michael McDermott

  • Central Nervous System Cancers

    Louis Burt Nabors;Mario Ammirati;Philip J. Bierman;Henry Brem

  • Recurrent meningioma Salvage therapy with long-acting somatostatin analogue

    Marc C. Chamberlain;Michael J. Glantz;Camilo E. Fadul

  • Temozolomide for treatment-resistant recurrent meningioma

    Marc C. Chamberlain;Denice D. Tsao-Wei;Susan Groshen

  • Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk, and determining benefit of treatment.

    Marc C. Chamberlain;Michael Glantz;Morris D. Groves;Wyndham H. Wilson

  • Leptomeningeal metastases: A rano proposal for response criteria.

    Marc C. Chamberlain;Larry Junck;Dieta Brandsma;Riccardo Soffietti

Frequent Co-Authors

Patrick Y. Wen
Patrick Y. Wen Harvard University
David Schiff
David Schiff University of Virginia
Tracy T. Batchelor
Tracy T. Batchelor Brigham and Women's Hospital
Lisa M. DeAngelis
Lisa M. DeAngelis Memorial Sloan Kettering Cancer Center
Mark R. Gilbert
Mark R. Gilbert National Institutes of Health
David A. Reardon
David A. Reardon Harvard University
Martin J. van den Bent
Martin J. van den Bent Erasmus University Rotterdam
Stuart A. Grossman
Stuart A. Grossman Johns Hopkins University
Victor A. Levin
Victor A. Levin The University of Texas MD Anderson Cancer Center
Michael D. Prados
Michael D. Prados University of California, San Francisco

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in a healthcare career but not ready for the long commitment of an MD program, several online alternatives offer flexible, affordable paths. Many registered nurses are upgrading their credentials through the cheapest online bsn programs, which often allow you to juggle work and study.

For those with a bachelor’s degree in another field, direct entry msn programs for non-nurses online pave a streamlined pathway to a master’s in nursing, opening up fast-track routes into advanced practice roles.

If you’re looking for accessibility and less competition, nursing schools with high acceptance rates can be a smart starting point. These schools offer more opportunities for applicants who may not have perfect academic backgrounds.

Not all medical careers require direct patient care—roles in healthcare administration are growing. Programs listed among the financial aid for medical billing and coding online classes make it possible to enter this in-demand sector, often with robust financial assistance options.

Best Scientists Citing Marc C. Chamberlain

Trending Scientists

Recently Published Articles